Cargando…
Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?
Patients with advanced heart failure have a high incidence of atrial fibrillation (AF) and develop into heart failure with reduced ejection fraction (HFrEF), and require higher doses of inotropes. However, it is uncertain about the differences in the effects of levosimendan in HFrEF patients with si...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995919/ https://www.ncbi.nlm.nih.gov/pubmed/36910542 http://dx.doi.org/10.3389/fcvm.2023.1084300 |
_version_ | 1784902927362555904 |
---|---|
author | Wang, Wenyan Li, Fawen Huang, Huihui Wu, Xin Tian, Weixiang Yu, Tao |
author_facet | Wang, Wenyan Li, Fawen Huang, Huihui Wu, Xin Tian, Weixiang Yu, Tao |
author_sort | Wang, Wenyan |
collection | PubMed |
description | Patients with advanced heart failure have a high incidence of atrial fibrillation (AF) and develop into heart failure with reduced ejection fraction (HFrEF), and require higher doses of inotropes. However, it is uncertain about the differences in the effects of levosimendan in HFrEF patients with sinus rhythm or AF. A total of 63 advanced HFrEF subjects (ejection fraction < 40%) were divided into sinus rhythm (SR, n = 34) and atrial fibrillation (AF, n = 29) cohorts. All patients received six cycles of intermittent repeated levosimendan infusion. After 3 months of treatment, B-type natriuretic peptide (BNP), estimated glomerular filtration rate, resting heart rate (rHR), creatinine, left ventricle ejection fraction (LVEF), left ventricular end diastolic diameter and blood pressure body weight, NYHA classification were measured. After completing the course of treatment, LVEF, BNP, and rHR were significantly decreased (p < 0.0.5), and no significant differences between the two groups were observed (p > 0.05). The NYHA classification improved in the SR group but not in the AF group. There was no significant difference between patients with different rHRs (≤70 bpm vs. >70 bpm) in the SR group (p > 0.05) or in the AF group (rHR ≤ 90 bpm vs. rHR >90 bpm) (p > 0.05). This study showed no difference in the therapeutic effect of intermittent repeated levosimendan infusion on advanced HFrEF with different heart rhythms (SR or AF); Advanced HFrEF patients receive levosimendan treatment without taking the inference of heart rhythm. |
format | Online Article Text |
id | pubmed-9995919 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99959192023-03-10 Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation? Wang, Wenyan Li, Fawen Huang, Huihui Wu, Xin Tian, Weixiang Yu, Tao Front Cardiovasc Med Cardiovascular Medicine Patients with advanced heart failure have a high incidence of atrial fibrillation (AF) and develop into heart failure with reduced ejection fraction (HFrEF), and require higher doses of inotropes. However, it is uncertain about the differences in the effects of levosimendan in HFrEF patients with sinus rhythm or AF. A total of 63 advanced HFrEF subjects (ejection fraction < 40%) were divided into sinus rhythm (SR, n = 34) and atrial fibrillation (AF, n = 29) cohorts. All patients received six cycles of intermittent repeated levosimendan infusion. After 3 months of treatment, B-type natriuretic peptide (BNP), estimated glomerular filtration rate, resting heart rate (rHR), creatinine, left ventricle ejection fraction (LVEF), left ventricular end diastolic diameter and blood pressure body weight, NYHA classification were measured. After completing the course of treatment, LVEF, BNP, and rHR were significantly decreased (p < 0.0.5), and no significant differences between the two groups were observed (p > 0.05). The NYHA classification improved in the SR group but not in the AF group. There was no significant difference between patients with different rHRs (≤70 bpm vs. >70 bpm) in the SR group (p > 0.05) or in the AF group (rHR ≤ 90 bpm vs. rHR >90 bpm) (p > 0.05). This study showed no difference in the therapeutic effect of intermittent repeated levosimendan infusion on advanced HFrEF with different heart rhythms (SR or AF); Advanced HFrEF patients receive levosimendan treatment without taking the inference of heart rhythm. Frontiers Media S.A. 2023-02-23 /pmc/articles/PMC9995919/ /pubmed/36910542 http://dx.doi.org/10.3389/fcvm.2023.1084300 Text en Copyright © 2023 Wang, Li, Huang, Wu, Tian and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Wang, Wenyan Li, Fawen Huang, Huihui Wu, Xin Tian, Weixiang Yu, Tao Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation? |
title | Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation? |
title_full | Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation? |
title_fullStr | Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation? |
title_full_unstemmed | Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation? |
title_short | Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation? |
title_sort | is there any difference in the therapeutic effects of levosimendan on advanced hfref patients with sinus rhythm or atrial fibrillation? |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995919/ https://www.ncbi.nlm.nih.gov/pubmed/36910542 http://dx.doi.org/10.3389/fcvm.2023.1084300 |
work_keys_str_mv | AT wangwenyan isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation AT lifawen isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation AT huanghuihui isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation AT wuxin isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation AT tianweixiang isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation AT yutao isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation |